Anti PD-L1 Durvalumab Combined With Cetuximab and Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Phase I/II Study
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Cetuximab (Primary) ; Durvalumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 20 Nov 2017 Planned End Date changed from 1 Jun 2024 to 1 Jan 2025.
- 20 Nov 2017 Planned primary completion date changed from 1 Jun 2021 to 1 Jan 2022.
- 20 Nov 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jan 2018.